Dr. Brian Persing, a medical oncologist and hematologist in Mobile, Alabama and member of the Association of Clinical Oncology (ASCO), the world’s leading professional organization representing nearly 45,000 oncology professionals, will testify before the House Appropriations Subcommittee on Labor Health and Human Services and Education today in support of increased federal funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control. He will also advocate for robust funding of the Advanced Research Projects Agency for Health (ARPA-H).
March 23, 2023
ASCO Member Testifies Before Congress Urging Significant Increase in Federal Cancer Research Funding
March 9, 2023
Today President Biden released his proposed Fiscal Year (FY) 2024 federal budget with an emphasis on increased funding for medical research and expanded access to health insurance.
February 8, 2023
“ASCO applauds President Biden’s focus on ‘ending cancer as we know it’ during the State of the Union address. We continue to urge the president to keep cancer care and research as top national priorities and are pleased with his plans to advance efforts to strengthen the Cancer Moonshot, improve cancer clinical trials, and foster breakthroughs through the Advanced Research Projects Agency for Health (ARPA-H).”
February 7, 2023
In anticipation of President Biden’s State of the Union Address, the Association for Clinical Oncology (ASCO) is urging the president to keep cancer care and research as top national priorities.
February 2, 2023
Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.
November 22, 2022
Prior authorization is harming individuals with cancer according to new survey results from the Association for Clinical Oncology (ASCO). The survey found that prior authorization delays necessary care, worsens cancer care outcomes, and diverts clinicians from caring for their patients.
September 12, 2022
“President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored the courage and commitment it would take to accomplish this then-audacious goal: ‘We choose to go to the moon in this decade and do the other things, not because they are easy, but because they are hard.’
July 22, 2022
Alexandria, Va.
April 7, 2022
The Association for Clinical Oncology (ASCO) today presented Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) with the annual Congressional Champion for Cancer Care Award in recognition of their commitment to legislation that focuses on medical innovation. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their care delivery teams.
April 7, 2022
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research.
April 4, 2022
The Association for Clinical Oncology (ASCO) congratulates Dr. Norman E. “Ned” Sharpless on his successful tenure as Director of the National Cancer Institute (NCI). During his five years at NCI, Dr. Sharpless guided the Institute to advance the goals of the Cancer Moonshot Initiative, including important work to modernize cancer clinical trials to reflect an improved understanding of biology and the new types of therapies available to treat cancer. We are hopeful that these efforts will endure even after Dr. Sharpless’ departure later this month.
March 29, 2022
While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H and its potential to innovate and expedite research, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI)
February 15, 2022
The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA).
February 2, 2022
The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.
December 10, 2021
The Association for Clinical Oncology (ASCO) appreciates that Congress passed legislation to prevent what would have been devastating reimbursement cuts for Medicare services from going into effect on January 1, 2022. With this short-term fix in place, we call on Congress and the Administration to work with healthcare providers on a true long-term solution for sustainable Medicare reimbursement that supports access to cancer care for all Americans.
Pages |